PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 25, 2016
Colorcon Acquires BASF’s Kollicoat IR Coating Systems
Author(s)Pharmaceutical Technology Editors
Colorcon Acquired BASF’s Kollicoat IR Coating System product line, which includes currently customer business, and inventory.
Advertisement
On May 25, 2016 Colorcon announced that it has acquired BASF’s Kollicoat IR Coating Systems product line, including its current customer businessand inventory. This will extend Colorcon’s existing film coating product line. Final closure of the transaction is subject to review of the Brazilian competition authorities. After completion of the transaction, Colorcon will serve all Kollicoat IR Coating Systems customers.
Colorcon recently
Source: Colorcon
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement